Advertisement

The effect of Momordica charantia capsule preparation on glycemic control in Type 2 Diabetes Mellitus needs further studies

Published:November 10, 2006DOI:https://doi.org/10.1016/j.jclinepi.2006.07.009

      Abstract

      Background and Objectives

      Momordica charantia, locally known as Ampalaya, is being widely used and advertised for its hypoglycemic effects. However, to date, no large clinical trial has been published on the efficacy of any type of preparation. The main objective of this study is to determine if addition of M. charantia capsules to standard therapy can decrease glycosylated hemoglobin (hemoglobin A1c or HbA1c) levels in diabetic patients with poor sugar control.

      Study Design and Setting

      A randomized, double-blind, placebo-controlled trial was conducted between April and September 2004 at the outpatient clinics of the Philippine General Hospital. The trial included 40 patients, 18 years old and above, who were either newly diagnosed or poorly controlled type 2 diabetics with A1c levels between 7% and 9%. On top of the standard therapy, the patients were randomized to either M. charantia capsules or placebo. The treatment group received two capsules of M. charantia three times a day after meals, for 3 months. The control group received placebo at the same dose. The primary efficacy endpoint was change in the A1c level in the two groups. The secondary efficacy endpoints included its effect on fasting blood sugar, serum cholesterol, and weight. Safety endpoints included effects on serum creatinine, hepatic transaminases (Alanine aminotransferase/ALT and Aspartate aminotransferase/AST), sodium, potassium, and adverse events.

      Results

      Baseline characteristics between the treatment and control groups were similar. The difference in mean change in A1c between the two groups was 0.22% in favor of M. charantia (95% CI: −0.40 to 0.84) with P=0.4825.There was no significant effect on mean fasting blood sugar, total cholesterol, and weight or on serum creatinine, ALT, AST, sodium, and potassium. There were few adverse events and these were generally mild.

      Conclusion

      This is the first randomized controlled trial to shed light on the issue concerning the hypoglycemic effects of M. charantia. The investigators targeted a 1% decline in A1c at the outset with an estimated power of 88%. With the observed decline of 0.24%, the achieved power was only 11%. For this reason, we are unable to make a definite conclusion about the effectiveness of M. charantia. However, the results of this study can be used estimate the sample size for bigger studies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Philippine Institute of Traditional and Alternative Health Care (PITAHC)
        Ampalaya (Momordica charantia).
        (Available at) (Accessed September 10, 2004)
      1. Torres, W. Momordica Charantia Linn (Family Cucurbitae–Chemistry and Pharmacology. Available at: http://www.charanteausa.com/ampalaya_archive/studies/1.doc.

        • Basch E.
        • Gabardi S.
        • Ulbricht C.
        Bitter melon (Momordica charantia): a review of efficacy and safety.
        Am J Health Syst Pharm. 2003; 60: 356-359
        • Baldwa V.S.
        • Bhandari C.M.
        • Pangaria A.
        • Goyal R.K.
        Clinical trials in patients with diabetes mellitus of an insulin-like compound obtained from a plant source.
        Ups J Med Sci. 1977; 82: 39-41
        • Welihinda J.
        • Karunanayake E.H.
        • Sheriff M.H.
        • Jayasinghe K.S.
        Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes.
        J Ethnopharmacol. 1986; 17 (In: Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003;60:356–359): 277-282
        • Shibib B.A.
        • Khan L.A.
        • Rahman R.
        Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase.
        Biochem J. 1993; 292 (In: Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003;60:356–359): 267-270
        • Yeh G.Y.
        • Eisenberg D.M.
        • Kaptchuk T.J.
        • Phillips R.S.
        Systematic review of herbs and dietary supplements for glycemic control in diabetes.
        Diabetes Care. 2003; 26 (Review): 1277-1294
        • Khanna P.
        • Jain S.C.
        • Panagariya A.
        • Dixit V.P.
        Hypoglycemic activity of polypeptide-p from a plant source.
        J Nat Prod. 1981; 44: 648-655
        • Leatherdale B.A.
        • Panesar R.K.
        • Singh G.
        • Atkins T.W.
        • Bailey C.J.
        • Bignell A.H.
        Improvement in glucose tolerance due to Momordica charantia (karela).
        BMJ (Clin Res Ed). 1981; 282: 1823-1824
        • Welihinda J.
        • Karunanayake E.H.
        • Sheriff M.H.
        • Jayasinghe K.S.
        Effect of Momordica charantia on the Glucose tolerance in maturity onset diabetes.
        J Ethnopharmacol. 1986; 17 (In: Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003;60:356–359): 277-282
        • Srivastava Y.
        • Venkatakrishna-Bhatt H.
        • Verma Y.
        • Venkaiah Y.
        • Raval B.H.
        Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation.
        Phytother Res. 1993; 7 (In: Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003;60:356–359): 285-289
        • Grover J.K.
        • Gupta S.R.
        Hypoglycemic activity of seeds of Momordica charantia.
        Eur J Pharmacol. 1990; 183: 1026-1027
        • Ahmad N.
        • Hassan M.R.
        • Halder H.
        • Bennoor K.S.
        Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients.
        Bangladesh Med Res Counc Bull. 1999; 25: 11-13
        • Rosales R.
        • Fernando R.
        An inquiry to the hypoglycemic action of Momordica charantia among type 2 diabetic patients.
        Phil J Inter Med. 2001; 39: 213-216
        • Tennekoon K.H.
        • Jeevathayaparan S.
        • Angunawala P.
        • Karunanayake E.H.
        • Jayasinghe K.S.
        Effect of Momordica charantia on key hepatic enzymes.
        J Ethnopharmacol. 1994; 44 (In: Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996;2(4):349–362): 93-97
        • Feng P.C.
        • Haynes L.J.
        • Magnus K.E.
        • Plimmer J.R.
        Pharmacological screening of some West Indian medicinal plants.
        J Pharm Pharmacol. 1962; 14 (In: Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996;2(4):349–362): 556-561
        • Dixit V.P.
        • Khann P.
        • Bhargava S.K.
        Effects of Momordica charantia L. fruit extract on the testicular function of dog.
        Planta Med. 1978; 34 (In: Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996;2(4):349–362): 280-286
        • Stepka W.
        • Wilson K.E.
        • Madge G.E.
        Antifertility investigation on Momordica.
        Lloydia. 1974; 37 (In: Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996;2(4):349–362): 645
        • Zhang Q.C.
        Bitter melon: a herb warranting a closer look.
        PWA Coalition Newsline. October 1992; (In: Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996;2(4):349–362): 48-49
        • Sharma V.N.
        • Sogani R.K.
        • Arora R.B.
        Some observations on hypoglycemic activity of Momordica charantia.
        Indian J Med Res. 1960; 48 (In: Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996;2(4):349–362): 471-477
        • Platel K.
        • Shurpalekar K.S.
        • Srinivasan K.
        Influence of bitter gourd (Momordica charantia) on growth and blood constituents in albino rats.
        Nahrung. 1993; 37 (In: Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996;2(4):349–362): 156-160
        • Patel J.C.
        • Dhirawani M.K.
        • Doshi J.C.
        “Karella” in the treatment of diabetes mellitus.
        Indian J Med Sci. 1968; 22 (In: Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996;2(4):349–362): 30-32
        • Hulin A.
        • Wavelet M.
        • Desbordes J.M.
        Intoxication aigue par Momordica charantia. A propos de deux eas.
        Medecine d'Affrique Noir. 1988; 35 ([French]): 671-674
      2. Charantia product information. Las Pinas City, Philippines; Herbcare Corporation. April 2002.